Kyowa Hakko Kirin Emphasizes Efforts On Kidney Disease With DPP-4
This article was originally published in PharmAsia News
Kyowa Hakko Kirin President Nobuo Hanai announced July 27 at a financial results briefing in Tokyo that the company will continue to provide a wide range of products targeting chronic kidney disease, with focus on renal anemia drugs NESP and ESPO.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.